CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN HUMAN GENOME SCIENCES, INC. AND GLAXO GROUP LIMITEDDevelopment and Commercialization Agreement • February 26th, 2009 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances • Delaware
THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT is made effective as of the 1st day of August, 2006 (“Effective Date”) by and between Human Genome Sciences, Inc., a Delaware corporation having its principal place of business at 14200 Shady Grove Road, Rockville, Maryland 20850 (“HGS”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its principal place of business at GlaxoWellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, United Kingdom (“GSK”). HGS and GSK shall be referred to herein collectively as “Parties” and individually as a “Party.”
SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT BY AND BETWEEN HUMAN GENOME SCIENCES, INC. AND H. THOMAS WATKINSEmployment Agreement • February 26th, 2009 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
WHEREAS, HUMAN GENOME SCIENCES, INC. (the “Company”) and H. THOMAS WATKINS (“Executive”) have entered into an employment agreement, dated as of November 21, 2004, as amended (the “Employment Agreement”);
FORM OF FIRST AMENDMENT TO EXECUTIVE AGREEMENTExecutive Agreement • February 26th, 2009 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
This FIRST AMENDMENT TO EXECUTIVE AGREEMENT (the “Amendment”) is entered into this ___day of December, 2008, by and between Human Genome Sciences, Inc. (the “Company”) and ___(the “Executive”) and serves to amend that certain Executive Agreement made and entered into as of the ___day of ___, 20___, by and between the Company and the Executive (the “Executive Agreement”).
